ChromaDex (NASDAQ:CDXC) Posts Earnings Results, Beats Expectations By $0.01 EPS

ChromaDex (NASDAQ:CDXC - Get Free Report) posted its quarterly earnings data on Tuesday. The company reported $0.03 earnings per share for the quarter, topping the consensus estimate of $0.02 by $0.01, Zacks reports. The firm had revenue of $18.20 million for the quarter, compared to analysts' expectations of $26.51 million. ChromaDex had a return on equity of 4.85% and a net margin of 1.62%. ChromaDex updated its FY 2025 guidance to EPS.

ChromaDex Stock Performance

Shares of NASDAQ CDXC traded up $0.01 during mid-day trading on Friday, reaching $7.70. The company had a trading volume of 1,083,271 shares, compared to its average volume of 865,008. The business's 50-day simple moving average is $5.77 and its 200 day simple moving average is $5.18. The firm has a market cap of $588.15 million, a price-to-earnings ratio of 770.77 and a beta of 2.21. ChromaDex has a one year low of $1.61 and a one year high of $9.18.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on CDXC shares. StockNews.com cut ChromaDex from a "strong-buy" rating to a "buy" rating in a research report on Thursday. LADENBURG THALM/SH SH raised their price target on ChromaDex from $6.80 to $8.10 and gave the stock a "buy" rating in a research report on Wednesday.

Remove Ads

Insider Activity at ChromaDex

In related news, Director Frank L. Jaksch, Jr. sold 37,161 shares of the firm's stock in a transaction dated Friday, December 13th. The stock was sold at an average price of $6.19, for a total value of $230,026.59. Following the sale, the director now directly owns 244,179 shares of the company's stock, valued at $1,511,468.01. This trade represents a 13.21 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. 9.64% of the stock is currently owned by insiders.

About ChromaDex

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.